Table 1 Demographic and clinical characteristics between patients with DAD and non-DAD

Age, years

79 (62–92)

79 (62–92)

80 (66–91)

Male

19 (70)

13 (72)

6 (67)

BMI

22.1 (16.4–28.8)

21.9 (17.1–28.8)

22.6 (16.4–26.2)

PaO₂/FiO₂

142 (48–258)

142 (48–203)

142 (60–258)

APACHE II score

29 (18–44)

28 (21–41)

34 (18–44)

Severity at diagnosis

 Mild

2 (7)

1 (5)

1 (11)

 Moderate

19 (70)

12 (67)

17 (78)

 Severe

6 (22)

5 (28)

1 (11)

Ventilation

 Noninvasive ventilation

10 (37)

6 (33)

4 (44)

 Mechanical ventilation

17 (63)

12 (67)

5 (56)

Underlying diseases

 Diabetes mellitus

6 (22)

3 (17)

3 (33)

 Malignance

6 (22)

3 (17)

3 (33)

 Immunosuppression

5 (19)

2 (11)

3 (33)

 End stage renal disease

1 (4)

0 (0)

1 (11)

Primary risk factor of ARDS

 Pneumonia

15 (56)

10 (56)

5 (56)

 Connective tissue disease

4 (15)

3 (17)

1 (11)

 Drug-induced

3 (11)

1 (6)

2 (22)

 Sepsis

2 (7)

1 (6)

1 (11)

 Malignancy

1 (4)

1 (6)

0 (0)

 Aspiration

1 (4)

1 (6)

0 (0)

 Radiation

1 (4)

1 (6)

0 (0)

 Duration of ARDS before death, d

18 (1–51)

18 (4–51)

18 (1–40)

Laboratory data at diagnosis

 WBC, per mm³

10,300 (300–37,800)

11,200 (300–37,800)

10,300 (2,300–30,000)

 CRP, mg/dL

13.6 (3.5–39.5)

15.3 (3.5–39.5)

11.2 (5.5–21.2)

 Albumin, g/dL

2.5 (1.4–3.3)

2.5 (1.4–3.2)

2.4 (1.4–3.3)

 Creatinine, mg/dL

1.14 (0.27–4.64)

1.13 (0.50–4.56)

1.33 (0.27–4.64)

 LDH, U/L

343 (212–1,192)

425 (212–1,192)

317 (233–705)

 KL-6*, U/mL

413 (194–1,780)

760 (194–1,780)

322 (229–1,322)

 KL-6* > 500 U/mL

12 (44)

11 (65)

1 (11)

Treatment

 Corticosteroid administration

14 (52)

10 (56)

4 (44)

 Methylprednisolone pulse therapy^†

13 (48)

10 (56)

3 (33)

Autopsy findings

 Weight of two lungs, g

1,380 (545–4,605)

1,455 (675–4,605)

1,100 (545–2,375)

 DAD

18 (67)

18 (100)

–

 Organizing pneumonia

7 (26)

–

7 (78)

 Pulmonary hemorrhage

2 (7)

–

2 (22)